Faeth Therapeutics
FTH
24 hedge funds and large institutions have $3.58M invested in Faeth Therapeutics in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 2 closing their positions.
0.09% more ownership
Funds ownership: 0.51% → 0.59% (+0.09%)
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
8% less funds holding
Funds holding: 26 → 24 (-2)
24% less capital invested
Capital invested by funds: $4.71M → $3.58M (-$1.12M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NM
Newtyn Management
New York
|
+$419K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$8.08K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$4.51K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$1.17K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$615 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$188K |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$136K |
| 3 |
Renaissance Technologies
New York
|
-$52.3K |
| 4 |
Millennium Management
New York
|
-$23.4K |
| 5 |
E
Ergoteles
New York
|
-$23.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HI
26
Harbour Investments
Madison,
Wisconsin
| $3 | – | – | – |
|
|
27
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$136K | -4,395 | Closed |
|
|
E
28
Ergoteles
New York
| – | -$23.3K | -776 | Closed |
|
FTH Hedge Fund Activity: Q2 2023 in Review
24 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Faeth Therapeutics (FTH) for Q2 2023, worth a combined $3.58M — down 24% from $4.71M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of FTH and 0 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 6 added.
The largest buyer was Newtyn Management, adding an estimated $419K. The largest seller was Morgan Stanley, cutting an estimated $188K.
- 24 institutional investors held Faeth Therapeutics (FTH) as of Q2 2023, down from 26 in Q1 2023.
- Funds reported $3.58M of Faeth Therapeutics stock for Q2 2023, down 24% quarter-over-quarter.
- 0 funds opened new Faeth Therapeutics positions in Q2 2023 and 2 closed out, a net change of -2 holders.
- The largest Faeth Therapeutics buyer in Q2 2023 was Newtyn Management, an estimated $419K added.
- The largest Faeth Therapeutics seller in Q2 2023 was Morgan Stanley, an estimated $188K sold.
Based on aggregated 13F filings for Q2 2023.